Losartan: First of a new class of angiotensin antagonists for the management of hypertension

Journal of Clinical Pharmacology

Volumn 36, Issue 1, 1996, Pages 3-12

  Carr, Albert A ^a   Prisant, L Michael ^b  

^a Circulatory Disease Center   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN POTASSIUM; NITRIC OXIDE; PHENOBARBITAL; POTASSIUM ION; PROSTANOID; WARFARIN;

ANGIONEUROTIC EDEMA; COUGHING; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VERTIGO;

EID: 0030024599     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04146.x     Document Type: Review

References (34)

1. Pals DT, Masucci FD, Sipos F, Denning GS Jr: A specific competitive antagonist of the vascular action of angiotensin II. Circ Res 1971;29:664-672.
2. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benefield P, Carinis DJ, et al: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.
3. Brunner HR, Nussberger J, Waeber B: Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system. J Hypertens Suppl 1993;11:S53-S58.
4. Sealey JE, Laragh JH: The renin-angiotensin system for normal regulation of blood pressure and sodium and potassium homeostasis. In, Laragh JH, Brenner BM (eds.): Hypertension: Pathophysiology, Diagnosis, and Management. Second edition. New York: Raven Press, 1995;1763-1796.
5. Laragh JH: The renin system and four lines of hypertension research: nephron heterogeneity, the calcium connection, the pro-renin vasodilator limb, and plasma renin and heart attack. Hypertension 1992;20:267-279.
6. Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH: Nephron heterogeneity with unsuppressible renin secretion: a cause of essential hypertension. In, Laragh JH, Brenner BM (eds.): Hypertension: Pathophysiology, Diagnosis, and Management. Second edition. New York: Raven Press, 1995;1405-1421.
7. Sealey JE, Campbell GH, Preibisz JJ: Hormone assays: renin, aldosterone, peripheral vein, renal vein and urinary assays: guidelines to methodology and interpretation. In, Laragh JH, Brenner BM (eds.). Hypertension: Pathophysiology, Diagnosis, and Management. New York: Raven Press, 1990;1443-1460.
8. Laragh JH, Lamport B, Sealey JE, Alderman MH: Diagnosis ex juvantibus: individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988;12: 223-226.
9. Tigerstedt R, Bergman PG: Niere und Kreislauf. Skand Arch Physiol 1898;7-8:223-271.
10. Bonner G: Do kinins play a significant role in the antihypertensive and cardioprotective effects of angiotensin I-converting enzyme inhibitors? In, Laragh JH, Brenner BM (eds.): Hypertension: Pathophysiology, Diagnosis, and Management. Second edition. New York: Raven Press, 1995;2877-2893.
11. Dzau VJ, Sasamura H, Hein L: Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens Suppl 1993;11:S13-S18.
12. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, et al: Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991;83:1333-1342.
13. Christen Y, Waeber B, Nussberger J, Lee RJ, Timmermans PBMWM, Brunner HR: Dose-response relationships following oral administration of DuP 753 to normal humans. Am J Hypertens 1991;4(suppl):350S-353S.
14. Munafo A, Christen Y, Nussberger J, Shum L, Lee RJ, Waeber B, et al: Drug concentration-response relationships in normal volunteers after oral administration of DuP 753, an angiotensin II antagonist (abstract). J Hypertens Suppl 1991;9:S468.
15. Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, et al: Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-521.
16. Doig JK, MacFadyen RJ, Sweet CS, Reid JL: Haemodynamics and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers. J Cardiovasc Pharmacol 1995;25:511-517.
17. Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL: Dose-ranging study of the angiotensin type 1 receptor antagonist losartan (DuP753-MK954), in salt-deplete normal man. J Cardiovasc Pharmacol 1993;21:732-738.
18. Doig JK, MacJadyen RJ, Lees KR, Sweet CS, Reid JL: A dose finding study of angiotensin II antagonist losartan (MK-954, DuP-753) in salt depleted subjects (abstract). Proc Br Pharmacol Soc 1991;33:542P.
19. Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, Brunner HR: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22: 339-347.
20. Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, et al: Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993;21:704-713.
21. Kiowski W, Linder L, Kleinloesem C, van Brummelen P, Buhler FR: Blood pressure control by the renin-angiotensin system in normotensive subjects: assessment by angiotensin converting enzyme and renin inhibition. Circulation 1992;85:1-8.
22. Nakashima M, Uematsu T, Kosuge K, Kanamaru M: Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333-335.
23. Nelson EB, Harm SC, Goldberg M, Shahinfar S, Goldberg A, Sweet CS: Clinical profile of the first angiotensin II (AT-1 specific) receptor antagonists. In. Laragh JH, Brenner BM (eds.): Hypertension: Pathophysiology, Diagnosis, and Management. Second edition. New York: Raven Press, 1995;2895-2916.
24. Sweet CS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ: Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994;7:1035-1040.
25. Bensoussan M, Mitchell T, Reilly T. Timmermans PBMWM, Verroust PJ, Ronco PM. Immunological reactivity of angiotensin II receptor antagonist: possible implications for receptor binding sites. Eur J Pharmacol 1993;247:169-175.
26. Chansel D, Vandermeersch S, Pham P, Ardaillou R: Characterization of [3H]losartan receptors in isolated rat glomeruli. Eur J Pharmacol 1993;247:193-198.
27. Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, Yoshinaga K: Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993;6:28-32.
28. Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T: Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994;7:1041-1044.
29. Chrysant SG, Danisa K, Kem DC, Dillard BL, Smith WJ, Frohlich ED: Racial differences in pressures, volume, and renin interrelationships in essential hypertension. Hypertension 1979;1:136-141.
30. Goldberg AI, Dunlay MC, Sweet CS: Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995;75:793-795.
31. Moan A, Risanger T, Eide I, Kjeldsen S: The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994;3:185-188.
32. Burnier M, Waeber B, Brunner HR: The advantages of angiotensin II antagonism. J Hypertens Suppl 1994;12:S7-S15.
33. Lacourcier̀e Y, Brunner H, Irwin R, Karlberg BE, Ramsay LE, Snavely DB, et al. and the Losartan Cough Study Group: Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-1393.
34. Ritter JM, Cockcroft JR, Sciberras DG, Goldberg MR: Clinical pharmacology of angiotensin and bradykinin in human forearm vasculature. J Hypertens Suppl 1993;11:S59-S61.